CARLSBAD, CA—Prasad Deepa, a director at Design Therapeutics, Inc. (NASDAQ:DSGN), recently sold 3,806 shares of the company’s common stock. The transaction, which occurred on December 18, 2024, was executed at a price of $6.27 per share, amounting to a total sale value of $23,863. Following this transaction, Deepa retains ownership of 20,000 shares in the company. According to InvestingPro analysis, Design Therapeutics maintains a GOOD financial health score, though investors should note the stock’s volatile price movements. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis through the Pro Research Report, available with an InvestingPro subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
